Preclinical Evaluation of a Radiolabeled Anti-PSMA Dimeric Aptamer in a Murine Model of Human Prostate Cancer.

Akesh Sinha, Darpan N Pandya, Prabhakar Eeka, Olcay Boyacioglu, William H Gmeiner, Thaddeus J Wadas

Abstract read

In one paragraph

Article in Molecules (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Akesh SinhaDepartment of Radiology, University of Iowa, Iowa City, IA 52242, USA.ORCID 0009-0007-4701-2147

Darpan N PandyaDepartment of Radiology, University of Iowa, Iowa City, IA 52242, USA.ORCID 0000-0001-6288-5172

Prabhakar EekaDepartment of Radiology, University of Iowa, Iowa City, IA 52242, USA.ORCID 0000-0001-6175-2941

Olcay BoyaciogluDepartment of Food Engineering, Adnan Menderes University, Zafer 09100, Turkey.ORCID 0000-0003-0436-3020

William H GmeinerDepartment of Cancer Biology, Wake Forest University Health Sciences, Winston-Salem, NC 27109, USA.ORCID 0000-0003-1883-3791

Thaddeus J WadasDepartment of Radiology, University of Iowa, Iowa City, IA 52242, USA.ORCID 0000-0002-9913-0336

Funding

Tumor Tissue CoreP30CA012197 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI Ruben A. Mesa · 1985 to 2026

$55.4M

Congressionally Directed Medical Research Programs W81XWH-19-1-0046NCI NIH HHS P30 CA012197NCI NIH HHS R21-CA219899NCI NIH HHS R21-CA227709

6 · The paper itself

Abstract

Prostate cancer is the third-leading cause of cancer death in men. Prostate-specific membrane antigen (PSMA) is a robust biomarker that is expressed in approximately 80% of patients diagnosed with prostate cancer; several theranostic strategies have emerged based upon targeting this biomarker. This report describes a dimeric aptamer complex (DAC) which is selective for PSMA

Indexed as

Antigens, SurfaceAptamers, NucleotideGlutamate Carboxypeptidase IIProstatic NeoplasmsRadiopharmaceuticalsAnimalsCell Line, TumorDisease Models, AnimalHumansMaleMiceRadioisotopesStreptavidinTissue DistributionZirconiumAntigens, SurfaceAptamers, NucleotideFOLH1 protein, humanGlutamate Carboxypeptidase IIRadioisotopesRadiopharmaceuticalsStreptavidinZirconiumZirconium-89aptamerprostate cancerprostate-specific membrane antigenradiochemistryzirconium-89

Identifiers

PMID41683470

DOI10.3390/molecules31030493

PMCPMC12899641

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.